Ensysce Biosciences Surges 96% Amid Patent News, Remains Volatile with High Risk Outlook Ahead

Technical Analysis

Ensysce Biosciences (ENSC) experienced a dramatic 96.26% price surge yesterday, closing at $3.67 on volume of 91.62 million shares—far exceeding its average daily volume of 75.36 thousand. This surge was accompanied by a trading range from $3.26 to $4.85, signaling heightened volatility. The stock remains below its 50-day moving average ($3.89) and significantly below the 200-day moving average ($5.93), indicating the recent rally has yet to reverse the longer-term downtrend. The RSI at 63 suggests moderate buying momentum but not yet overbought conditions. The MACD remains negative (-0.77), pointing to lingering bearish momentum despite the price spike. Immediate support lies near $3.56, with resistance around $3.90. Given the stop-loss level at $3.53, short-term risk is elevated due to the large intraday price fluctuations and elevated ATR (13.99).

For April 24, 2025, technical factors suggest possible continued elevated volatility. The price may attempt to consolidate above the $3.60 support but could encounter resistance near $3.90. If volume normalizes, a pullback may occur, otherwise, upward momentum could persist if positive catalysts emerge.

Over the week, the stock is likely to remain volatile, trading within the $3.30–$4.00 range as the market digests recent news and awaits the earnings announcement on May 9. A sustained breakout above $4.00 with volume confirmation would be needed to challenge the 50-day MA and potentially reverse the medium-term bearish trend.

Fundamental Analysis

Ensysce Biosciences remains a clinical-stage pharmaceutical firm with high speculative risk. Earnings remain deeply negative with a trailing twelve-month EPS of -$11.45 and an unattractive negative P/E of -0.32. The current market capitalization is approximately $6.04 million, reflecting micro-cap risk and limited institutional interest.

Nonetheless, the recent developments provide fundamental catalysts: the company secured a U.S. patent for its enzyme-cleavable methadone prodrugs, targeting opioid use disorder (OUD), a sizable market with strong demand for safer therapies. This patent strengthens its intellectual property position and potential future revenue streams. Furthermore, the exercise of warrants generating $2.2 million in gross proceeds improves the company's cash runway; this capital infusion is critical for a clinical-stage developer lacking product revenues.

Intrinsic value remains challenging to estimate given zero current revenues and ongoing losses. Long-term valuation hinges on successful clinical development, regulatory approvals, and commercialization of its pipeline. Given the early patent milestone and innovative technology platform (TAAP™ and MPAR®), the company holds long-term potential if it can navigate clinical and regulatory risks effectively.

Stock Performance Outlook

- Next trading day: Likely elevated volatility with a possible consolidation or moderate pullback; range expected between $3.50 and $4.00.

- Upcoming week: Price may exhibit sideways movement or modest retracement; likely trading between $3.30 and $4.00 as investors weigh recent news against lack of revenues and upcoming earnings.

Long-Term Investment Potential

Ensysce Biosciences presents a high-risk, high-reward profile typical of clinical-stage biopharma firms. The recent patent allowance increases intrinsic value prospects, but the path to profitability remains uncertain and long. The substantial losses and low market cap highlight liquidity and execution risks. If clinical programs advance and the company secures regulatory approvals, long-term upside is possible, but this requires a significant time horizon and tolerance for volatility.

Overall Evaluation

Ensysce Biosciences aligns with a Hold categorization. The recent news flow and price action have improved sentiment significantly, supported by patent milestones and financing activities. However, the stock remains fundamentally speculative with negative earnings, a low market cap, and substantial volatility. A cautious stance is justified as the stock seeks confirmation of sustained upward momentum and clinical progress before transitioning into a definitive Buy or Sell posture.